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Background: Although it is well established that systemic lupus erythematosus (SLE) 
negatively affects pregnancy outcomes, there is insufficient evidence on the effect of lupus 
nephritis (LN) on antenatal management and pregnancy outcomes. We performed a systematic 
review and meta-analysis to determine the association of LN with management and pregnancy 
outcomes in SLE patients.
Methods: Embase, Medline, Cochrane, and ClinicalTrials.gov were carefully searched for rel-
evant English and Chinese language studies. A total of 2,987 articles were reviewed. Data were 
extracted that compared management and pregnancy outcomes in SLE pregnant women with 
LN vs without LN. Risk of bias was assessed by a modified version of the Newcastle-Ottawa 
Scale and the STROBE checklist. Combined odds ratios (OR) and 95% confidence intervals 
(CI) were obtained and sensitivity analysis was performed using RevMan 5.3 software.
Results: Sixteen studies, including 1,760 pregnant patients with SLE, were included. Gestational 
hypertension (OR5.65, 95% CI2.94–10.84), preeclampsia (OR2.84, 95% CI1.87–4.30), 
SLE flare (OR2.66, 95% CI1.51–4.70), renal flare (OR15.18, 95% CI5.89–39.14), proteinu-
ria (OR8.86, 95% CI4.75–16.52), and hypocomplementemia (OR2.86, 95% CI1.68–4.87) 
were significantly affected in pregnant women with LN. Anti-Sjögren’s syndrome-related anti-
gen A/Ro autoantibodies were negatively associated with pregnant women with LN (OR0.57, 
95% CI0.33–0.98). Pregnant women with LN presented a significant decrease in live births 
(OR0.62, 95% CI0.49–0.80) and a significant increase in preterm births (OR1.92, 95% 
CI1.49–2.49) and fetal growth restriction (OR1.43, 95% CI1.08–1.91). Regarding ante-
natal management, steroids (OR2.48, 95% CI1.59–3.87) and immunosuppressant treatment 
(OR6.77, 95% CI3.30–13.89) were more frequently used in women with LN.
Conclusion: This review identified a significant association between the aforementioned 
outcomes and SLE pregnant patients with LN. In patients with SLE, LN increased the risks for 
adverse pregnancy outcomes and the use of medication. Therefore, special treatment and close 
monitoring should be allocated to pregnant women with LN.
Keywords: systemic lupus erythematosus, lupus nephritis, maternal outcomes, fetal outcomes, 
antenatal management
Introduction
Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease that 
primarily affects women of childbearing age. Women with SLE have a normal fertility 
rate,1 making pregnancy a frequent subject of interest in these patients. Pregnancy 
and SLE are reciprocally adversely affected. Pregnancy may increase SLE activity, 
and have short or long-term adverse effects on renal function, while SLE can result 
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in adverse pregnancy outcomes and complications such 
as preeclampsia, preterm delivery, and fetal loss.2 In past 
decades, SLE was a contraindication for pregnancy. How-
ever, with improvements in treatment and multidisciplinary 
management, the success rate of delivery in women with SLE 
has greatly improved.3 Women with SLE can have successful 
pregnancies given that there is optimal timing of conception 
and close management during pregnancy.
The effects of lupus nephritis (LN) on fetal and maternal 
outcomes have been extensively studied. Khamashta reported 
that LN is a risk factor for pregnancy loss, especially in 
patients with renal impairment.4 Moreover, higher incidences 
of fetal loss, intrauterine growth restriction (IUGR), and 
gestational hypertension have been reported, even in patients 
with LN with non-active SLE.5 Smyth et al reported that LN 
was associated with premature birth and hypertension during 
pregnancy in a systematic review in 2010.6 However, these 
reports had several limitations, such as a retrospective study 
design, insufficient number of participants, and limited scope 
of analyzed outcomes.
Therefore, we conducted a systematic review and meta-
analysis of management and pregnancy outcome in women 
with SLE with or without LN to examine the effect and 
quantifiably clarify the effect of LN on pregnancy outcome, 
which also serves as an updated systemic review with a more 
complete analysis of pregnancy outcomes and antenatal 
management.
Materials and methods
Literature search
We carefully searched Embase, Medline database, 
ClinicalTrials.gov, and Cochrane Database of Randomized 
Controlled Trials for relevant English and Chinese language 
studies on June 28, 2017. In addition, we examined the 
reference lists of the literature that met the inclusion criteria 
of our study. The search was conducted in accordance with 
the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses guidelines.7 During the process of 
searching, we used a protocol that included the Cochrane 
Collaboration’s search strategy for randomized controlled 
trials and related exploded terms, including Medical Subject 
Headings in combination with keywords and the following 
terms: systemic lupus erythematosus, SLE, lupus nephritis, 
pregnancy, pregnancy outcomes, maternal outcomes, fetal 
outcomes, and gynecology.
The search was carried out in June 2017, and only 
included studies that were published since the year 2000. 
Studies published prior to the year 2000 were excluded 
from this analysis because of more recent changes in health 
care facilities, medical conditions, laboratory data, and 
diagnostic criteria, and would therefore introduce bias to the 
analysis. The full results of our search strategy are shown in 
Appendix 1 Tables S1–S4.
Study selection
Studies were included if:
1. They compared pregnant women with SLE with LN (the 
experimental group) versus pregnant women with SLE 
without LN (non-LN) (the control group).
2. They reported adverse maternal and/or fetal outcomes.
Studies were excluded if:
1. They did not compare pregnant women with LN versus 
pregnant women with SLE without LN (only included 
the experimental group without including the control 
group).
2. They compared pregnant women with SLE versus preg-
nant women without SLE (not the objective of the present 
study).
3. They were reviews, editorials, guidelines, case reports, 
letters, abstracts, or summaries of meetings.
4. They did not involve pregnant women.
5. They did not report adverse maternal and/or fetal 
outcomes.
6. They were duplicates of the same studies.
Two authors (JY W and JH M) independently performed 
the first selection of studies based on titles and abstracts, 
and then examined the selected full texts. Disagreements 
between reviewers were resolved by consensus. If no agree-
ment could be reached, the matter was resolved through 
discussion with another author (WH Z).
Analysis of outcomes
The following information was extracted from each included 
study: 
u฀ Names of authors
u฀ Publication year
u฀ Period of participants’ enrollment
u฀ Geographical region of the study
u฀ Type of study
u฀ Types and total number of participants in each group
u฀ Number of events in each group
u฀ Baseline characteristics of the participants
u฀ Diagnostic criteria of SLE, criteria for the histological 
diagnosis of LN, SLE activity score, and diagnostic 
criteria of flares
u฀ Outcomes of interest
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The following outcomes were defined as follows: 
Maternal outcomes
 1. Spontaneous abortion: spontaneous termination of 
pregnancy prior to 20 weeks of gestation, or prior to 
24 weeks of gestation.
 2. Gestational hypertension: the presence of blood 
pressure ?140/90 mmHg on at least two occasions 
?6 h apart, arising de novo after the 20th week of 
pregnancy.
 3. Preeclampsia: pregnancy-induced hypertension with 
proteinuria ?0.3 g/L/d in the absence of urinary tract 
infection, or abrupt onset of hypertension and proteinu-
ria after 20 weeks of gestation.
 4. SLE flare: considered as: 1) new signs of active disease 
by clinical and laboratory variables or change in therapy; 
2) change in Systemic Lupus Erythematosus Disease 
Activity Index 2000 (SLEDAI-2k) score;8 3) change in 
Systemic Lupus Erythematosus Disease Activity Index 
(SLEDAI) score;9 4) change in Lupus Activity Index 
in Pregnancy;10 5) change in the physician global 
assessment.11
 5. Renal flare: considered as worsening proteinuria 
(defined as an increase by 2 g/24 h if baseline proteinuria 
was ?3.5 g/24 h, or doubling of proteinuria in women 
with previous nephrotic range proteinuria), urinary casts, 
dysmorphic hematuria, reduced levels of C3 and/or C4, 
or rise in serum creatinine of ?30%.12,13
 6. Cesarean section: included all of the operative 
indications.
 7. Premature rupture of membranes (PROM): diagnosed 
as a rupture of the amniotic sac prior to the onset of 
labour.
 8. Gestational diabetes mellitus (GDM): defined as any 
degree of glucose intolerance with onset or first recogni-
tion during pregnancy. The diagnosis of GDM is made 
if there is at least one abnormal value (?5.1 mmol/L, 
10.0 mmol/L, 8.5 mmol/L for fasting, 1-h, and 2-h 
plasma glucose concentration, respectively) after a 75 
g oral glucose tolerance test undertaken at 26–28 weeks 
gestation.
 9. Antiphospholipid antibodies (aPL) and antiphospholipid 
syndrome (APS): aPL included lupus anticoagulant, 
anticardiolipin antibodies, and B2-glycoprotein I; APS 
was defined according to the Sapporo criteria.14
10. Active disease at conception: defined according to the 
criteria of each study.
11. Proteinuria during pregnancy: proteinuria ?300 mg/24 h.
12. Positivity for anti-Sjögren’s syndrome-related antigen A 
(anti-SSA)/Ro autoantibodies.
13. Hypocomplementemia: defined as low C3 and/or 
C4 levels.
Fetal outcomes
1. Live birth: the birth of a living child.
2. Stillbirth or intrauterine fetal death: spontaneous termi-
nation of pregnancy after 20 weeks of gestation or after 
24 weeks of gestation.
3. Preterm birth: delivery ?37 weeks of gestation.
4. Low birth weight (LBW)/IUGR/small for gestational age 
(SGA): neonatal birth weight ?2,500 g, or an estimated 
birth weight of less than the lower 10% limit of the CI 
of the normal curve for gestation weight.
5. Neonatal lupus: included all types of neonatal lupus, as 
well as either cutaneous lesions and/or congenital heart 
block.
6. Congenital malformation: included all types of congenital 
malformation.
7. One-min Apgar scores: method for quickly evaluating 
the health of a neonate.
Antenatal management (management of medication 
use during pregnancy)
It included all forms of the following drugs, regardless of 
dosage and method of administration:
u฀ Steroids
u฀ Antimalarials
u฀ Immunosuppressants
u฀ Aspirin
Data collection
A standardized data extraction sheet was developed to record 
data. One author (JY W) extracted the aforementioned data 
from the included studies, and the other author (JH M) 
checked the extracted data. Disagreements were resolved by 
discussion between the two authors. If no agreement could be 
reached, another author (WH Z) would resolve the matter.
Assessment of risk of bias
The quality of the studies was reviewed by JY W and JH M 
using a modified version of the Newcastle-Ottawa Scale 
(NOS) for cohort studies and cross-sectional studies.15,16 
Disagreements were resolved by consensus. This scale 
assesses risk of bias in the following three parameters: 
selection, comparability, and exposure/outcome. The total 
scores were 9 for cohort studies and 8 for cross-sectional 
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studies. A score ?7 in cohort studies and ?6 in cross-
sectional studies were indicative of a high quality study.17 
Furthermore, each study was assessed using the Strength-
ening the Reporting of Observational Studies in Epidemi-
ology (STROBE) checklist, which is a 22-item checklist 
that assesses the essential items of observational studies.18 
The purpose of STROBE is not to assess quality, but to 
ensure clear presentation of the study. The results of the 
full-modified versions of the NOS and STROBE checklists 
are shown in Appendix 2 Tables S5 and S6 and Appendix 3 
Table S7. Funnel plots were used to visually estimate pub-
lication bias.
Statistical analysis
Dichotomous data were used for comparisons. The meta-
analyses were performed by calculating odds ratios (OR) 
using a fixed- or random-effects model according to their het-
erogeneity. The heterogeneity across studies was assessed by 
the Q-statistic and I2 statistic tests. When P
Q
?0.1 or I2?50%, 
the heterogeneity was considered significant. Therefore, 
a random-effects model was used to calculate the pooled 
OR, and the sensitivity test was conducted to exclude studies 
that increased the heterogeneity. Otherwise, the fixed-effects 
model was used. Outcomes that were included in less than 
three studies or that were defined differently were evaluated 
qualitatively rather than by meta-analysis. All tests were two-
tailed, and P?0.05 was considered statistically significant. 
Analyses were carried out using RevMan 5.3 software.
Results
Study selection
A flow diagram of the study selection process is shown in 
Figure 1. A total of 2,987 articles were extracted from the 
aforementioned databases. Following the screening of titles 
and abstracts, 104 full-text articles were assessed for eligi-
bility. Finally, 16 articles were included in the quantitative 
synthesis of this systematic review.
Study characteristics
The main characteristics of the included studies are shown 
in Table 1. There were 15 retrospective studies and one 
cross-sectional study. Patients were enrolled between the 
years 1970 and 2015, and studies were conducted in different 
regions such as Europe, South Africa, Canada, the US, and 
some Asian countries.
The 16 studies included a total of 665 LN pregnan-
cies (experimental group) and 1,095 non-LN pregnancies 
(control group). The maternal age at delivery was reported 
in all studies, and all participants were of childbearing age. 
However, some studies only reported the mean age of patients 
Figure 1 Flow diagram demonstrating the study selection process.
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in both group. Additionally, not all participants in each study 
had biopsy-proven LN. Some studies exclusively included 
patients with biopsy-proven LN (n5) as the experimental 
group, while others had varying percentages of patients with 
biopsy-proven LN (n5). However, all participants were 
confirmed to have been diagnosed with SLE and LN upon 
enrollment in each study.
The diagnostic criteria for SLE varied in each study. The 
1997 American College of Rheumatology criteria were the 
mostly widely used (12/16). Others used the older version, 
while one did not indicate which criteria were used. The 
definitions of disease activity also varied. The majority 
(7/16) used the SLE disease activity index (SLEDAI or 
SLEDAI-2K), while six studies defined disease activity 
according to organ involvement and laboratory abnormalities. 
LN associated with SLE was determined primarily accord-
ing to the 1995 classification system of renal biopsies of the 
World Health Organization (7/16), while others also used 
clinical and laboratory records. The definition of SLE flare 
during pregnancy varied as well. Most studies (13/16) defined 
it as new signs of active disease by clinical and laboratory 
variables or change in therapy (Table 2).
Risk of bias within studies
The risk of bias within the studies was assessed by a modified 
version of the NOS for cohort studies and cross-sectional 
studies, and a STROBE checklist. The NOS and STROBE 
scores from each study are shown in Table 1. The total 
NOS scores were 9 for the cohort studies and 8 for the cross-
sectional studies. The STROBE checklist has a total score 
of 22. All included studies were of high quality.
Maternal outcomes
We analyzed 13 maternal outcomes. Among them, 10 were 
included in the quantitative synthesis, and three were ana-
lyzed qualitatively. The outcomes are shown in Appendix 4 
Table S8.
Quantitative synthesis and heterogeneity analyses
In the present analysis, maternal outcomes in pregnant 
women with SLE with LN were compared with maternal 
outcomes in pregnant women with SLE without LN. Pregnant 
women with LN showed a significant association with 
gestational hypertension (OR5.65, 95% CI2.94–10.84), 
preeclampsia (OR2.84, 95% CI1.87–4.30), renal flare 
(OR15.18, 95% CI5.89–39.14), proteinuria (OR8.86, 
95% CI4.75–16.52), and hypocomplementemia (OR2.86, Ta
b
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Table 2 Outcomes reported, SLE diagnostic criteria, lupus nephritis diagnostic criteria, disease activity rates, and ﬂare deﬁnition upon 
study enrollment in the studies included for analysis
Study Maternal outcomes Fetal outcomes SLE 
diagnostic 
criteria
LN 
diagnosis 
criteria
Disease 
activity
Flare
Carmona et al21 Spontaneous abortion, gestational 
hypertension, preeclampsia, cesarean 
section, ﬂare, renal ﬂare, aPL positive, 
active disease at conception
Fetal loss, stillbirth, premature 
birth, live birth
1 1 4 1
Cavallasca et al49 Spontaneous abortion, gestational 
hypertension, preeclampsia
Stillbirth, premature birth, full-term 
birth, LBW
2 NA 1 1
Whitelaw et al50 Spontaneous abortion Premature birth, full-term birth, 
IUGR, live birth
1 1 3 1
Wagner et al22 Spontaneous abortion, gestational 
hypertension, preeclampsia, 
cesarean section
Premature birth, full-term birth, 
SGA, fetal loss, stillbirth, neonatal 
death, neonatal lupus
1 1 1 1
Al Arfaj and Khalil51 Miscarriages Premature birth, full-term birth, 
stillbirth, IUGR, live birth
2 NA NA 1
Gladman et al20 Spontaneous abortion, gestational 
hypertension, preeclampsia, GDM, 
medicine, aPL positive, SLE ﬂare
Live birth, stillbirth, LBW, 
congenital malformation, neonatal 
lupus
NA NA 2, 6 2
Bramham et al24 Preeclampsia, cesarean section, SLE ﬂare, 
renal ﬂare, aPL positive, APS, medication
Live birth, intrauterine death, SGA, 
1-min Apgar ?7
1 1 1 1
Ko et al52 Miscarriages Stillbirth, neonatal death, live birth, 
preterm birth, full-term birth, IUGR
1 NA 3 1
Kwok et al26 Spontaneous abortion, SLE ﬂares, 
preeclampsia, APS, medications
Stillbirth, fetal loss, SGA, IUGR, 
preterm birth
2 1 3, 5 1
Saavedra et al13 Spontaneous abortion, cesarean section, 
active SLE at conception, SLE ﬂares, 
PROM, renal ﬂare, preeclampsia, APS, 
proteinuria, medication
Stillbirth fetal loss, neonatal death, 
live birth, LBW, preterm birth
1, 2 1, 3 1 1
Fatemi et al53 Abortion, SLE ﬂare, preeclampsia, APS, 
low C3, C4, medication
Stillbirth, premature birth 1 2 2 3
Madazli et al54 IUGR and/or preeclampsia Fetal loss, premature birth, IUGR 
and/or preeclampsia
1 NA 1 1
Lv et al25 Gestational hypertension, preeclampsia, 
ﬂare, renal damage, low C3, low C4, acL 
and B2GPI positive, proteinuria
Live births, gestational age, SGA, 
fetal loss, fetal malformation, 1-min 
Apgar scores
1 NA 7 4
Mbuli et al55 Miscarriage, cesarean section, ﬂare, 
preeclampsia
Stillbirth, premature birth, full-term 
birth, live birth
1 NA 1 1
Ku et al23 SLE ﬂare, proteinuria, 
hypocomplementemia, disease activity, 
gestational hypertension, proteinuria
Fetal loss, premature birth, IUGR, 
neonatal lupus, neonatal heart 
disease, 1-min Apgar scores
1 NA 2 1
Teh et al19 SLE ﬂare, aPL positive, hypertension, 
preeclampsia, PROM, eclampsia, GDM
Premature birth, IUGR, fetal loss, 
live births
1 1 3, 8 1, 3, 5
Notes: Diagnostic criteria: 1) ACR 1997 criteria;56 2) ACR 1982 criteria.57 Histological lupus nephritis: 1) The 1995 World Health Organization categorization for lupus 
nephritis;58 2) the 2004 classiﬁcation of the International Society of Nephrology/Renal Pathology Society;59 3) nephritis was established clinical and biochemically. Activity: 1) 
Organ involvement and laboratory abnormalities; 2) SLEDAI-2k; 3) SLEDAI; 4) lupus activity criteria count; 5) Systemic Lupus Erythematosus Pregnancy Disease Activity 
Index; 6) Adjusted Mean Systemic Lupus Erythematosus Disease Activity Index; 7) LAI-P; 8) PGA. Flare: 1) New signs of active disease by clinical and laboratory variables or 
change in therapy; 2) SLEDAI-2k; 3) SLEDAI score; 4) change in LAI-P; 5) change in PGA. aPL include lupus anticoagulant, anticardiolipin antibodies, and B2-glycoprotein I. 
APS was deﬁned according to the Sapporo criteria.
Abbreviations: SLE, systemic lupus erythematosus; LN, lupus nephritis; aPL, antiphospholipid antibodies; LBW, low birth weight; NA, not available; IUGR, intrauterine 
growth restriction; SGA, small for gestational age; GDM, gestational diabetes mellitus; APS, antiphospholipid syndrome; PROM, premature rupture of membranes; B2GPI, 
B2-glycoprotein; ACR, American College of Rheumatology; SLEDAI-2k, Systemic Lupus Erythematosus Disease Activity Index 2000; SLEDAI, Systemic Lupus Erythematosus 
Disease Activity Index; LAI-P, Lupus Activity Index in Pregnancy; PGA, Physician Global Assessment.
95% CI1.68–4.87), with low statistical heterogeneity in all 
outcomes, and the fixed-effects model was used. SLE flare 
was also significantly affected in pregnant women with LN 
(OR2.66, 95% CI1.51–4.70), with statistical heterogeneity 
across studies (I269%, P
Q
0.001), and the random-effects 
model was used.
There was less positivity for anti-SSA/Ro autoantibodies 
in pregnant women with SLE with LN compared with those 
Therapeutics and Clinical Risk Management 2018:14 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
891
Pregnancy outcomes of lupus nephritis
without LN (OR0.57, 95% CI0.33–0.98), with statistical 
heterogeneity across studies (I243%, P
Q
0.15), and the 
fixed-effects model was used.
However, spontaneous abortion (which was divided into 
two subgroups according to different outcome definitions) 
(OR1.25, 95% CI0.92–1.70), cesarean section (OR1.17, 
95% CI0.79–1.74), and aPL positivity and APS (OR0.98, 
95% CI0.71–1.35) were not significantly different between 
pregnant women with LN and those without LN. The results 
of maternal outcomes are shown in Figure 2 and Table 3.
Sensitivity analyses
Regarding SLE flare, the statistical heterogeneity was high 
(I269%, P
Q
0.001). Therefore, sensitivity analyses were 
performed (Table 4A). The sensitivity analyses showed 
that after omitting the studies by Bramham et al or Lv et al, 
SLE flare was still significantly affected in pregnant women 
with LN (OR3.12, 95% CI1.83–5.32, I259%, P
Q
0.02; 
OR2.22, 95% CI1.34–3.68, I259%, P
Q
0.02, respec-
tively). These data indicated that the pooled results remained 
robust in the SLE flare outcome.
Figure 2 (Continued)
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Figure 2 (Continued)
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Qualitative analyses
There were two articles that studied PROM,13,19 both of 
which showed no significant difference between pregnant 
women with LN and those without LN. The same result 
was found regarding GDM.19,20 Saavedra et al found that 
more pregnancies with LN had evidence of active disease 
at conception (25.7% vs 6.6%, P0.009), and active dis-
ease at conception was a predictor for any type of maternal 
complication (OR16.4, 95% CI1.97–137.2, P0.01).13 
Carmona et al did not identify any differences between 
the two groups.21 The results are shown in Appendix 5 
Table S11A.
Fetal outcomes
We analyzed seven fetal outcomes. Among them, four 
were included in the quantitative synthesis, and three were 
qualitative analyses. The outcomes are shown in Appendix 4 
Table S9.
Quantitative synthesis and heterogeneity analyses
In these analyses, fetal outcomes in pregnant women with 
SLE with LN were compared with fetal outcomes in preg-
nant women with SLE without LN. Pregnant women with 
LN showed a significant decrease in live births (OR0.62, 
95% CI0.49–0.80), with statistical heterogeneity across 
Figure 2 Maternal outcomes observed in pregnant women with SLE with lupus nephritis versus those without lupus nephritis.
Abbreviations: SLE, systemic lupus erythematosus; LN, lupus nephritis; aPL, antiphospholipid antibodies positive; APS, antiphospholipid syndrome; anti-SSA/Ro, anti-
Sjögren’s syndrome-related antigen A/Ro autoantibodies positive.
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studies (I20%, P
Q
0.53), and the fixed-effects model 
was used. In addition, preterm births were significantly 
higher in neonates born from pregnant women with LN 
(OR1.92, 95% CI1.49–2.49), with low heterogeneity 
(I20%, P
Q
0.76), and the fixed-effects model was used. 
There were significantly more neonates who were clas-
sified with LBW/IUGR/SGA in pregnant women with 
LN (OR1.43, 95% CI1.08–1.91), with low hetero-
geneity (I20%, P
Q
0.76), and the fixed-effects model 
was used.
However, stillbirths (divided into two subgroups accord-
ing to different outcome definitions, 20 weeks and 24 weeks) 
were not significantly different between pregnant women 
with LN and those without LN, either in subgroups or in total 
(OR1.25, 95% CI0.92–1.70). The results of fetal outcomes 
are shown in Figure 3 and Table 3.
Qualitative analyses
A total of six cases of neonatal lupus were identified, and all 
the included studies showed no significant difference between 
pregnant women with LN and those without LN.20,22,23
Five cases of congenital malformation were found in 
two included studies.20,23 There was no significant difference 
between pregnant women with LN and those without LN. 
Gladman et al reported one infant with cleft lip; one with 
cleft lip/palate, facial palsy, and visual/hearing impairment; 
and one with bilateral 2nd and 3rd toe syndactyly. Ku et al 
reported one neonate with tetralogy of Fallot, and another 
with atrial septal defect.
There were three studies that reported 1-min Apgar 
scores. Bramham et al analyzed neonates with 1-min 
Apgar scores ?7 and found no difference between the 
LN and non-LN groups.24 Lv et al and Ku et al recorded 
1-min Apgar scores (mean o standard deviation), although 
neither study found a significant difference between the 
two groups.23,25 The results are shown in Appendix 5 
Table S11B.
Antenatal management
We analyzed four antenatal management outcomes. Among 
them, three outcomes were included in the quantitative 
synthesis, and one outcome was analyzed qualitatively. The 
outcomes are shown in Appendix 4 Table S10.
Quantitative synthesis and heterogeneity analyses
In the present study, antenatal management in pregnant 
women with SLE with LN was compared with antenatal man-
agement in pregnant women with SLE without LN. Pregnant 
Table 3 Results of meta-analysis
Outcomes  
analyzed
No. of 
studies 
involved (n)
OR with  
95% CI
I2
Maternal outcomes
Spontaneous abortion 9 1.25 (0.92, 1.70) 0%
Gestational 
hypertension
5 5.65 (2.94, 10.84) 0%
Preeclampsia 10 2.84 (1.87, 4.30) 0%
SLE ﬂare 9 2.66 (1.51, 4.70) 69%
Renal ﬂare 4 15.18 (5.89, 39.14) 0%
Cesarean section 5 1.17 (0.79, 1.74) 38%
aPL and APS 8 0.98 (0.71, 1.35) 0%
Proteinuria 3 8.86 (4.75, 16.52) 0%
SSA 4 0.57 (0.33, 0.98) 43%
Hypocomplementemia 3 2.86 (1.68, 4.87) 0%
Fetal outcomes
Live birth 15 0.62 (0.49, 0.80) 0%
Stillbirth 9 1.68 (0.95, 2.98) 0%
Preterm birth 13 1.92 (1.49, 2.49) 0%
LBW/IUGR/SGA 11 1.43 (1.08, 1.91) 0%
Antenatal management
Steroids 5 2.48 (1.59, 3.87) 27%
Antimalarials 5 0.67 (0.30, 1.49) 72%
Immunosuppressives 5 6.77 (3.30, 13.89) 53%
Abbreviations: OR, odds ratio; SLE, systemic lupus erythematosus; aPL, 
antiphospholipid antibodies; APS, antiphospholipid syndrome; SSA, Sjögren’s 
syndrome-related antigen A positive LBW, low birth weight; IUGR, intrauterine 
growth restriction; SGA, small for gestational age.
Table 4 Sensitivity analyses
A
Study omitted P
Q
I2 OR 95% CI
Carmona et al21 0.01 61% 3.11 1.80, 5.37
Gladman et al20 0.0006 73% 2.69 1.38, 5.24
Bramham et al24 0.02 59% 3.12 1.83, 5.32
Kwok et al26 0.001 71% 2.51 1.36, 4.62
Saavedra et al13 0.0008 72% 2.58 1.36, 4.89
Lv et al25 0.02 59% 2.22 1.34, 3.68
Mbuli et al55 0.0006 73% 2.63 1.40, 4.96
Ku et al23 0.0006 73% 2.63 1.40, 4.96
Teh et al19 0.0007 72% 2.63 1.38, 5.01
B
Gladman et al20 0.002 79% 0.66 0.20, 2.12
Bramham et al24 0.002 79% 0.64 0.21, 1.95
Kwok et al26 0.25 28% 0.89 0.54, 1.46
Saavedra et al13 0.004 78% 0.59 0.21, 1.62
Fatemi et al53 0.02 69% 0.52 0.23, 1.16
C
Bramham et al24 0.28 20% 4.66 2.04, 10.66
Kwok et al26 0.005 81% 7.34 1.63, 33.09
Saavedra et al13 0.007 80% 7.8 1.34, 45.38
Fatemi et al53 0.08 61% 11.64 3.94, 34.38
Notes: (A) Outcome: SLE ﬂare. (B) Outcome: antimalarials. (C) Outcome: immu-
nosuppressant-azathioprine. 
Abbreviations: SLE, systemic lupus erythematosus; OR, odds ratio.
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women with LN presented a significant association with 
steroid treatment (OR2.48, 95% CI1.59–3.87), with sta-
tistical heterogeneity across studies (I227%, P
Q
0.24), and 
the fixed-effects model was reported. Immunosuppressant 
treatment was divided into three subgroups according to dif-
ferent outcome definitions (azathioprine, cyclosporin A, and 
all immunosuppressants), and was significantly associated 
with pregnant women with SLE with LN, either in subgroups 
Figure 3 (Continued)
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or in total (OR6.77, 95% CI3.30–13.89), with statistical 
heterogeneity across studies (I253%, P
Q
0.04), and the 
random-effects model was used.
However, antimalarial treatment was not significantly dif-
ferent between pregnant women with LN and those without 
LN, with statistical heterogeneity (I272%, P
Q
0.006), and 
the random-effects model was used.
The results of antenatal outcomes are shown in Figure 4 
and Table 3.
Sensitivity analyses
Regarding the use of antimalarials, statistical heterogeneity 
was high (I272%, P
Q
0.006). Therefore, sensitivity analyses 
were performed (Table 4B). The sensitivity analyses 
showed that after omitting the study by Kwok et al, anti-
malarial treatment was still not significantly different 
between pregnant women with LN and those without LN 
(OR0.89, 95% CI0.54–1.46, I228%, P
Q
0.25). These 
data indicated that the pooled result remained robust in the 
antimalarials outcome.
We also found that the immunosuppressant treatment 
outcome had high heterogeneity (I253%, P
Q
0.04), and 
that the high heterogeneity was mainly from the azathioprine 
subgroup (I271%, P
Q
0.01), with the other two subgroups 
having low heterogeneity (cyclosporin: I20%, P
Q
0.43; All 
immunosuppressants: I20%, P
Q
0.42). Therefore, sensitivity 
analyses were performed (Table 4C). After omitting the study 
by Bramham et al, immunosuppressant treatment was still 
significantly associated with pregnant women with SLE 
with LN, either in the azathioprine subgroup (OR4.66, 
95% CI2.04–10.66, I220%, P
Q
0.28) or in total (OR4.72, 
95% CI2.84–7.83, I20%, P
Q
0.53). These data indicated 
that the pooled results remained robust in the immunosup-
pressant treatment outcome.
Qualitative analyses
There were two studies that analyzed the use of aspirin during 
pregnancy.24,26 Bramham et al found that patients with LN 
were more frequently taking low-dose aspirin compared 
with patients without LN. However, Kwok et al found no 
difference between the two groups. The results are shown 
in Appendix 5 Table S11C.
Risk of bias across studies
Funnel plots allowed for visualization of the relationship of 
publication bias among the included studies in this meta-
analysis. Figures 5–7 show the funnel plots evaluating the 
three categories of outcomes (maternal outcomes, fetal 
outcomes, and antenatal management). In these analyses, 
the shape of each funnel plot appeared almost symmetrical, 
meaning that publication bias was mildly evident across 
all studies.
Discussion
This systematic review provided a complete overview of 
published reports on management and pregnancy outcome 
in women with LN. Overall, we found that LN was associ-
ated with higher risk for adverse maternal outcomes such as 
gestational hypertension, preeclampsia, SLE flare, renal flare, 
proteinuria during pregnancy, and hypocomplementemia. 
Furthermore, LN was associated with lower rate of live 
births, higher rate of preterm births, and significantly higher 
Figure 3 Fetal outcomes observed in pregnant women with SLE with lupus nephritis versus those without lupus nephritis.
Abbreviations: SLE, systemic lupus erythematosus; LN, lupus nephritis; LBW, low birth weight; IUGR, intrauterine growth restriction; SGA, small for gestational age.
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number of infants with growth restriction (LBW/IUGR/
SGA). There were also significant differences in medications 
used. For example, women with SLE with LN had increased 
treatment with steroids and immunosuppressants compared 
with those without LN.
Recently, a systematic review of women with SLE and 
the risk of preterm birth showed that preterm birth was 
significantly associated with patients with SLE with a his-
tory of LN, or in patients with active nephritis.27 However, 
the review mainly focused on the association of SLE or 
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Figure 4 Antenatal management observed in pregnant women with SLE with lupus nephritis versus those without lupus nephritis.
Abbreviations: SLE, systemic lupus erythematosus; LN, lupus nephritis.
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Figure 5 Funnel plot of the association between lupus nephritis and maternal 
outcomes.
Abbreviations: SE, standard error; OR, odds ratio; aPL, antiphospholipid antibodies 
positive; APS, antiphospholipid syndrome; anti-SSA/Ro, anti-Sjögren’s syndrome-
related antigen A/Ro autoantibodies positive; SLE, systemic lupus erythematosus.
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Figure 6 Funnel plot of the association between lupus nephritis and fetal 
outcomes.
Abbreviations: SE, standard error; OR, odds ratio; LBW, low birth weight; IUGR, 
intrauterine growth restriction; SGA, small for gestational age.
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Figure 7 Funnel plot of the association between lupus nephritis and antenatal 
management.
Abbreviations: SE, standard error; OR, odds ratio.
LN with preterm birth and did not include other pregnancy 
outcomes. Similarly, a systemic review of pregnancy out-
comes in women with SLE from 2010 showed that LN was 
associated with premature birth and hypertension during 
pregnancy,6 which was consistent with our analysis. More-
over, the authors indicated the importance of optimal timing 
of pregnancy in patients with SLE with LN. The present 
study serves as an updated systemic review, and included 
a more complete analysis of pregnancy outcomes and ante-
natal management. Notably, antenatal management was not 
reported in previous studies. Another meta-analysis showed 
that SLE had a strong effect on adverse maternal and fetal 
outcomes following pregnancy, including cesarean section, 
preeclampsia, hypertension, fetal loss, premature birth, 
SGA, and congenital defects.28 However, the previous meta-
analysis reported pregnancy outcomes in women with SLE 
and those without SLE, and the included studies were limited 
regarding some of the reported outcomes. In our analysis, 
we focused on the differences between pregnant women with 
SLE with LN and those without LN.
The prevalence of SLE is 14.6–50.8 cases per 100,000 
people,29 and thus there is a low prevalence of these preg-
nancy outcomes. Therefore, studies of the associations of LN 
with pregnancy outcomes are limited, and they have obvious 
variations in study design, diagnostic criteria, statistical 
methods, bias, and outcomes analyzed. Furthermore, the 
study population and status of LN also varied in these studies. 
Performing a systemic review, including meta-analyses, 
allowed for the accumulation of more data for determining 
the actual associations in the larger population.
LN was shown to be a strong risk factor for gestational 
hypertension, preeclampsia, preterm birth, and fetal loss, 
which was supported by other studies.1,3,4,6 One review recom-
mended that for patients with SLE with LN, SLE should be 
in the remission stage for at least 6 months before conception 
because adverse pregnancy outcomes are related to active 
nephritis.5 This may be because of compromised microcir-
culation in the uteroplacental vessels of SLE patients with 
high blood pressure and LN. Additionally, pregnancy itself 
contributes partially to renal impairment and subsequently 
to renal failure in the late stage of pregnancy.30 Clinically, 
24-h urinary protein is an indicator of renal function. Our 
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analysis showed that proteinuria (300 mg/24 h) had high 
incidence in women with nephritis, which was consistent 
with previous studies. This suggested that renal involvement 
and the presence and degree of proteinuria at the time of con-
ception may contribute to adverse pregnancy outcomes.22,31 
Thus, it is critical to continuously monitor renal function and 
proteinuria in pregnant patients with LN.
The flare rate in LN remains controversial. In our analysis, 
the SLE flare rate and renal flare rate were both higher in the 
LN group. By contrast, a previous study found lower flare 
rates in the nephritis group compared with all patterns of 
SLE (however, the sample-size in the study was relatively 
small).31 In a study of 113 pregnancies with LN, there were 
30% with flares. The study also indicated the risk factor of 
renal flare associated with renal function during pregnancy: 
patients with either proteinuria ?1 g/24 h or glomerular 
filtration rate ?60 mL/min/body surface area had a ninefold 
increased risk of flare.12 Clinically, a woman with a history 
of LN and/or renal flare during pregnancy is more likely to 
have flares in future pregnancies.32
Anti-Ro/SSA antibodies have previously been shown 
to be related to miscarriages and loss of pregnancy,33,34 
although this association has not yet been proven in more 
recent studies.35,36 The main adverse outcomes related to 
anti-Ro/SSA antibodies are neonatal lupus and congenital 
heart block. However, in the present analysis, there was 
a lower percentage of patients who were positive for anti-
SSA antibodies in the LN group (Figure 2), which has not 
been reported in other studies. Unfortunately, our analysis 
included a small number of participants. Therefore, further 
investigation into the association of LN with neonatal lupus 
and congenital heart block is warranted.
Complement is important for the development of the 
placenta and normal fetus.37 It is estimated that up to 20% 
of first trimester pregnancy losses are associated with 
hypocomplementemia.38 SLE flares are often associated 
with low C3 and C4 levels,39 and normal levels of C3 and 
C4 are associated with a reduction in SLE flares.40 In the 
present analysis, we found a significant association between 
LN and hypocomplementemia, which was consistent with 
the observation that LN was associated with a higher risk of 
pregnancy loss and SLE flare.
A growth-restricted neonate has three times the risk on 
neonatal death compared with one with normal weight.41 
Adverse consequences of fetal growth restriction include 
respiratory infection, cardiovascular or metabolic diseases, 
and neurodevelopmental retardation.37 In our review, we 
merged three definitions of growth restriction as a single fetal 
outcome (LBW/SGA/IUGR) to clarify the association with 
fetal growth restriction, because the included studies used 
them interchangeably. However, it is important to clarify 
the definitions of the three terms. LBW refers only to infants 
with birth weight ?2,500 g, regardless of the gestational 
age and cause.42 SGA refers to infants whose weight is less 
than the lower 10% limit of the CI of the normal curve for 
gestation weight.43 IUGR refers to processes that can limit 
the potential for intrauterine growth of the fetus.44 SLE 
has been reported to be associated with poor fetal growth 
in many studies.1,3,29,32 The common underlying factor was 
vascular pathology that reduced uteroplacental perfusion. 
Lupus increases the frequency of fetal growth restriction and 
preterm birth by 30%–50%, which are also affected by the 
type of nephritis and hypertension.44 This was fully demon-
strated in our results. These observations indicate that more 
attention should be paid to fetal growth status in pregnant 
women with LN.
Immunosuppressive therapy for SLE is often used when 
there is a flare, or as maintenance therapy for patients in 
remission. Because most immunosuppressants are terato-
genic, azathioprine and cyclosporin are the most commonly 
used during pregnancy, given that they were proven to be 
safe for use during pregnancy.45 When we compared the 
use of immunosuppressants and steroids in women with LN 
and those without LN, we found that women with nephritis 
tended to have used more medication, which indirectly indi-
cated that the disease was unstable. Antimalarials are now 
a first-line therapy for SLE in pregnancy. They are safe for 
pregnancy, and are proven to be associated with a reduced 
risk of congenital heart block in neonates.46 Aspirin has been 
proven to prevent preeclampsia in women with SLE.47 The 
European League Against Rheumatism and European Renal 
Association-European Dialysis and Transplant Association 
guidelines recommend low-dose aspirin therapy for all 
patients to prevent preeclampsia.48 Our analysis included a 
limited number of studies that involved the use of aspirin, 
and may represent a direction for further study.
LN as one of the most serious manifestations of SLE 
apparently increases the risk of both maternal and fetal 
adverse outcomes. Our data further support the importance of 
pregnancy planning, pre-conception evaluation, and counsel-
ing of women with SLE, especially those with LN. Patients 
should be informed that disease flare is common during 
pregnancy, especially in nephritis patients. Therefore, we 
highly recommend LN patients to be in remission stage for 
at least 6 months before conception in order to get positive 
pregnancy outcome and avoid disease flare. Our study also 
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emphasizes the importance of motoring fetal growth status, 
as fetal growth restriction accounts for one-fifth of the fetuses 
among nephritis patients. Monitoring strategies should be 
strengthened in these women during pregnancy.
The present study is noteworthy for several reasons. 
This is the first systemic review and meta-analysis that com-
prehensively compared pregnancy outcomes and antenatal 
management between pregnant women with SLE with and 
without LN. Additionally, several outcomes were analyzed 
from data from large sample sizes from different settings. 
The outcomes were complete and involved almost every key 
aspect of pregnancy, especially the use of medication, which 
has not been reported in previous reviews. Furthermore, the 
present review included the use of NOS and STROBE to 
evaluate the quality of the included studies, and we performed 
sensitivity analyses for all results with high heterogeneity.
Limitations
First, all included studies were retrospective observational 
studies, in which the results might have reporting bias. 
Second, a mild level of publication bias existed across stud-
ies. Third, there were variations in diagnostic criteria, the 
measurement of SLE activity, and the percentage of patients 
who underwent renal biopsy among studies.
Conclusion
Patients with LN tend to have an increased risk for gesta-
tional hypertension, preeclampsia, SLE flare, renal flare, 
proteinuria, and hypocomplementemia during pregnancy, 
compared with those without LN. Additionally, LN was 
shown to contribute to increased incidence of fetal loss, 
premature birth, and fetal growth restriction. Increased use 
of steroids and immunosuppressants was found in pregnant 
women with LN. Therefore, pre-pregnancy counseling, opti-
mal timing of conception, and close monitoring in antenatal 
care, especially of renal function and blood pressure, are 
critical in SLE patients with LN. Further studies should be 
conducted on antenatal management, including assessment 
and medication use in pregnant women with LN.
Acknowledgment
The work was supported by funding from the Shanghai 
Municipal Health and Family Planning Commission 
(15GWZK0701).
Author contributions
All authors contributed toward data analysis, drafting and 
critically revising the paper and agree to be accountable for 
all aspects of the work.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Meyer O. Making pregnancy safer for patients with lupus. Joint Bone 
Spine. 2004;71(3):178–182.
 2. Chen S, Sun X, Wu B, Lian X. Pregnancy in women with systemic 
lupus erythematosus: a retrospective study of 83 pregnancies at a single 
centre. Int J Environ Res Public Health. 2015;12(8):9876–9888.
 3. Lateef A, Petri M. Systemic lupus erythematosus and pregnancy. Rheum 
Dis Clin North Am. 2017;43(2):215–226.
 4. Khamashta MA. Systemic lupus erythematosus and pregnancy. Best 
Pract Res Clin Rheumatol. 2006;20(4):685–694.
 5. Stanhope TJ, White WM, Moder KG, Smyth A, Garovic VD. Obstetric 
nephrology: lupus and lupus nephritis in pregnancy. Clin J Am Soc 
Nephrol. 2012;7(12):2089–2099.
 6. Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. 
A systematic review and meta-analysis of pregnancy outcomes in 
patients with systemic lupus erythematosus and lupus nephritis. Clin J 
Am Soc Nephrol. 2010;5(11):2060–2068.
 7. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for 
reporting systematic reviews and meta-analyses of studies that evalu-
ate healthcare interventions: explanation and elaboration. BMJ. 2009; 
339:b2700.
 8. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus 
disease activity index 2000. J Rheumatol. 2002;29(2):288–291.
 9. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Deri-
vation of the SLEDAI. A disease activity index for lupus patients. The 
Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35(6): 
630–640.
 10. Buyon JP, Kalunian KC, Ramsey-Goldman R, et al. Assessing dis-
ease activity in SLE patients during pregnancy. Lupus. 1999;8(8): 
677–684.
 11. Harrington JT. The uses of disease activity scoring and the physician 
global assessment of disease activity for managing rheumatoid arthritis 
in rheumatology practice. J Rheumatol. 2009;36(5):925–929.
 12. Imbasciati E, Tincani A, Gregorini G, et al. Pregnancy in women with 
pre-existing lupus nephritis: predictors of fetal and maternal outcome. 
Nephrol Dial Transplant. 2009;24(2):519–525.
 13. Saavedra MA, Cruz-Reyes C, Vera-Lastra O, et al. Impact of previ-
ous lupus nephritis on maternal and fetal outcomes during pregnancy. 
Clin Rheumatol. 2012;31(5):813–819.
 14. Wilson WA, Gharavi AE, Koike T, et al. International consensus state-
ment on preliminary classification criteria for definite antiphospholipid 
syndrome: report of an international workshop. Arthritis Rheum. 1999; 
42(7):1309–1311.
 15. Busby J, Purdy S, Hollingworth W. A systematic review of the mag-
nitude and cause of geographic variation in unplanned hospital admis-
sion rates and length of stay for ambulatory care sensitive conditions. 
BMC Health Serv Res. 2015;15:324.
 16. Ajmani GS, Suh HH, Wroblewski KE, Pinto JM. Smoking and olfac-
tory dysfunction: a systematic literature review and meta-analysis. 
Laryngoscope. 2017;127(8):1753–1761.
 17. Bhindi B, Wallis CJD, Nayan M, et al. The association between vasec-
tomy and prostate cancer: a systematic review and meta-analysis. JAMA 
Intern Med. 2017;177(9):1273–1286.
 18. Vandenbroucke JP, von Elm E, Altman DG, et al; STROBE Initiative. 
Strengthening the Reporting of Observational Studies in Epidemi-
ology (STROBE): explanation and elaboration. PLoS Med. 2007; 
4(10):e297.
 19. Teh CL, Wan SA, Cheong YK, Ling GR. Systemic lupus erythematosus 
pregnancies: ten-year data from a single centre in Malaysia. Lupus. 
2017;26(2):218–223.
 20. Gladman DD, Tandon A, Ibañez D, Urowitz MB. The effect of lupus 
nephritis on pregnancy outcome and fetal and maternal complications. 
J Rheumatol. 2010;37(4):754–758.
 erapeutics and Clinical Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/therapeutics-and-clinical-risk-management-journal
Therapeutics and Clinical Risk Management is an international, peer-
reviewed journal of clinical therapeutics and risk management, focusing 
on concise rapid reporting of clinical studies in all therapeutic areas, 
outcomes, safety, and programs for the effective, safe, and sustained 
use of medicines. This journal is indexed on PubMed Central, CAS, 
EMBase, Scopus and the Elsevier Bibliographic databases. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Therapeutics and Clinical Risk Management 2018:14 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
901
Pregnancy outcomes of lupus nephritis
 21. Carmona F, Font J, Moga I, et al. Class III–IV proliferative lupus nephritis 
and pregnancy: a study of 42 cases. Am J Reprod Immunol. 2005; 
53(4):182–188.
 22. Wagner SJ, Craici I, Reed D, et al. Maternal and foetal outcomes in preg-
nant patients with active lupus nephritis. Lupus. 2009;18(4):342–347.
 23. Ku M, Guo S, Shang W, et al. Pregnancy outcomes in Chinese patients 
with systemic lupus erythematosus (SLE): a retrospective study of 
109 pregnancies. PLoS One. 2016;11(7):e0159364.
 24. Bramham K, Hunt BJ, Bewley S, et al. Pregnancy outcomes in systemic 
lupus erythematosus with and without previous nephritis. J Rheumatol. 
2011;38(9):1906–1913.
 25. Lv J, Wang W, Li Y. Clinical outcomes and predictors of fetal and 
maternal consequences of pregnancy in lupus nephritis patients. Int 
Urol Nephrol. 2015;47(8):1379–1385.
 26. Kwok LW, Tam LS, Zhu T, Leung YY, Li E. Predictors of maternal 
and fetal outcomes in pregnancies of patients with systemic lupus 
erythematosus. Lupus. 2011;20(8):829–836.
 27. Wei S, Lai K, Yang Z, Zeng K. Systemic lupus erythematosus and risk 
of preterm birth: a systematic review and meta-analysis of observational 
studies. Lupus. 2017;26(6):563–571.
 28. Bundhun PK, Soogund MZ, Huang F. Impact of systemic lupus erythemato-
sus on maternal and fetal outcomes following pregnancy: a meta-analysis of 
studies published between years 2001–2016. J Autoimmun. 2017;79:17–27.
 29. Singh AG, Chowdhary VR. Pregnancy-related issues in women with 
systemic lupus erythematosus. Int J Rheum Dis. 2015;18(2):172–181.
 30. Koh JH, Ko HS, Lee J, et al. Pregnancy and patients with preexisting 
lupus nephritis: 15 years of experience at a single center in Korea. 
Lupus. 2015;24(7):764–772.
 31. Huong DL, Wechsler B, Vauthier-Brouzes D, Beaufils H, Lefebvre G, 
Piette JC. Pregnancy in past or present lupus nephritis: a study of 32 preg-
nancies from a single centre. Ann Rheum Dis. 2001;60(6):599–604.
 32. Clowse ME. Lupus activity in pregnancy. Rheum Dis Clin North Am. 
2007;33(2):237–252, v.
 33. Hull RG, Harris EN, Morgan SH, Hughes GR. Anti-Ro antibodies and 
abortions in women with SLE. Lancet. 1983;2(8359):1138.
 34. Watson RM, Braunstein BL, Watson AJ, Hochberg MC, Provost TT. 
Fetal wastage in women with anti-Ro(SSA) antibody. J Rheumatol. 
1986;13(1):90–94.
 35. Brucato A, Doria A, Frassi M, et al. Pregnancy outcome in 100 women 
with autoimmune diseases and anti-Ro/SSA antibodies: a prospective 
controlled study. Lupus. 2002;11(11):716–721.
 36. Martínez-Sánchez N, Pérez-Pinto S, Robles-Marhuenda Á, et al. Obstet-
ric and perinatal outcome in anti-Ro/SSA-positive pregnant women: 
a prospective cohort study. Immunol Res. 2017;65(2):487–494.
 37. Regal JF, Gilbert JS, Burwick RM. The complement system and adverse 
pregnancy outcomes. Mol Immunol. 2015;67(1):56–70.
 38. Cunningham DS, Tichenor JR Jr. Decay-accelerating factor protects 
human trophoblast from complement-mediated attack. Clin Immunol 
Immunopathol. 1995;74(2):156–161.
 39. Birmingham DJ, Irshaid F, Nagaraja HN, et al. The complex nature of 
serum C3 and C4 as biomarkers of lupus renal flare. Lupus. 2010;19(11): 
1272–1280.
 40. Stohl W, Hiepe F, Latinis KM, et al; BLISS-52 Study Group; BLISS-76 
Study Group. Belimumab reduces autoantibodies, normalizes low com-
plement levels, and reduces select B cell populations in patients with sys-
temic lupus erythematosus. Arthritis Rheum. 2012;64(7):2328–2337.
 41. Garite TJ, Clark R, Thorp JA. Intrauterine growth restriction increases 
morbidity and mortality among premature neonates. Am J Obstet 
Gynecol. 2004;191(2):481–487.
 42. WHO. Aspects of low birth weight. Report of the expert committee of 
maternal child health. WHO Tech Rep. 1961;217:3–16.
 43. Goto E. Maternal anthropometry to predict small for gestational age: a 
meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2016;203:193–198.
 44. Valero De Bernabé J, Soriano T, Albaladejo R, et al. Risk factors for low birth 
weight: a review. Eur J Obstet Gynecol Reprod Biol. 2004;116(1):3–15.
 45. Kattah AG, Garovic VD. Pregnancy and lupus nephritis. Semin Nephrol. 
2015;35(5):487–499.
 46. Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use 
of hydroxychloroquine is associated with a reduced risk of recurrent 
anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal 
lupus. Circulation. 2012;126(1):76–82.
 47. Schramm AM, Clowse ME. Aspirin for prevention of preeclampsia in 
lupus pregnancy. Autoimmune Dis. 2014;2014:920467.
 48. Bertsias GK, Tektonidou M, Amoura Z, et al; European League Against 
Rheumatism and European Renal Association-European Dialysis and 
Transplant Association. Joint European League Against Rheumatism and 
European Renal Association-European Dialysis and Transplant Association 
(EULAR/ERA-EDTA) recommendations for the management of adult and 
paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
 49. Cavallasca JA, Laborde HA, Ruda-Vega H, Nasswetter GG. Maternal 
and fetal outcomes of 72 pregnancies in Argentine patients with systemic 
lupus erythematosus (SLE). Clin Rheumatol. 2008;27(1):41–46.
 50. Whitelaw DA, Hall D, Kotze T. Pregnancy in systemic lupus erythe-
matosus: a retrospective study from a developing community. Clin 
Rheumatol. 2008;27(5):577–580.
 51. Al Arfaj AS, Khalil N. Pregnancy outcome in 396 pregnancies in 
patients with SLE in Saudi Arabia. Lupus. 2010;19(14):1665–1673.
 52. Ko HS, Ahn HY, Jang DG, et al. Pregnancy outcomes and appropriate 
timing of pregnancy in 183 pregnancies in Korean patients with SLE. 
Int J Med Sci. 2011;8(7):577–583.
 53. Fatemi A, Fard RM, Sayedbonakdar Z, Farajzadegan Z, Saber M. The 
role of lupus nephritis in development of adverse maternal and fetal 
outcomes during pregnancy. Int J Prev Med. 2013;4(9):1004–1010.
 54. Madazli R, Yuksel MA, Oncul M, Imamoglu M, Yilmaz H. Obstetric 
outcomes and prognostic factors of lupus pregnancies. Arch Gynecol 
Obstet. 2014;289(1):49–53.
 55. Mbuli L, Mapiye D, Okpechi I. Lupus nephritis is associated with 
poor pregnancy outcomes in pregnant SLE patients in Cape Town: 
a retrospective analysis. Pan Afr Med J. 2015;22:365.
 56. Hochberg MC. Updating the American College of Rheumatology 
revised criteria for the classification of systemic lupus erythematosus. 
Arthritis Rheum. 1997;40(9):1725.
 57. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the 
classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 
25(11):1271–1277.
 58. Churg J, Bernstein J, Glassock RJ. Renal Diseases: Classification and 
Atlas of Glomerular Diseases. 2nd ed. New York: Igaku-Shoin; 1995.
 59. Weening JJ, D’Agati VD, Schwartz MM, et al; International Society of 
Nephrology Working Group on the Classification of Lupus Nephritis; 
Renal Pathology Society Working Group on the Classification of Lupus 
Nephritis. The classification of glomerulonephritis in systemic lupus 
erythematosus revisited. Kidney Int. 2004;65(2):521–530.
